Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Department of Thoracic Oncology, Airway Research Center North (ARCN), German Center for Lung Research, LungenClinic Grosshansdorf, Grosshansdorf, Germany.
Lung Cancer. 2019 Aug;134:245-253. doi: 10.1016/j.lungcan.2019.06.007. Epub 2019 Jun 19.
The development of PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitors (CPI) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). The potential of immunotherapy (IO) to induce durable responses for a subset of patients represents a therapeutic milestone. After the approval of front-line single agent pembrolizumab, IO-based combinations are rapidly entering clinical practice resulting in a fast change of treatment algorithms for advanced NSCLC. We hereby summarize the recent first-line phase 3 trials evaluating PD-(L)1 blockade plus chemotherapy (ChT) and PD-1 plus CTLA-4 CPI for advanced NSCLC and provide potential treatment recommendations.
PD-1、PD-L1 和 CTLA-4 免疫检查点抑制剂（CPI）的发展彻底改变了晚期非小细胞肺癌（NSCLC）的治疗方式。免疫疗法（IO）有潜力为一部分患者诱导持久应答，这是一个治疗的里程碑。在一线单药帕博利珠单抗获得批准后，基于 IO 的联合治疗方案迅速进入临床实践，导致晚期 NSCLC 的治疗方案迅速改变。在此，我们总结了最近评估 PD-（L）1 阻断联合化疗（ChT）和 PD-1 联合 CTLA-4 CPI 治疗晚期 NSCLC 的一线 III 期临床试验，并提供潜在的治疗建议。
